About
ArisGlobal builds LifeSphere, an AI-enabled and interoperable software platform covering drug development, pharmacovigilance, regulatory affairs, medical affairs, quality, and compliance. It sells primarily to pharmaceutical and biotechnology companies, CROs, and government health authorities, differentiating through domain-specific life-sciences workflows, broad interoperability, and AI capabilities.
Market
ArisGlobal competes in enterprise cloud software for life-sciences drug development, especially pharmacovigilance and drug safety, regulatory affairs, medical affairs, quality, and analytics. It positions LifeSphere as an integrated, AI-enabled platform: Unify connects data and processes across domains, NavaX adds agentic AI, and MultiVigilance embeds production-ready automation. Its differentiation is the combination of cloud-native SaaS, cross-domain interoperability and scalability, and automation for compliance-heavy workflows rather than a single point solution.
ArisGlobal primarily serves global life-sciences and biopharmaceutical companies, contract research organizations (CROs), and government health authorities, particularly those managing mission-critical drug-development, safety, regulatory, medical-affairs, and quality workflows. Its main users and buyers are enterprise leaders and teams in pharmacovigilance/drug safety, regulatory affairs, medical affairs, quality, and related operations.
At a Glance
Problem
Life-sciences companies must manage increasingly complex regulatory requirements, large and growing volumes of adverse-event reports, and fragmented workflows across drug development, safety, regulatory, quality, and medical affairs. The pain is operational as well as economic: manual review and case processing consume specialist labor, slow safety decisions and regulatory submissions, increase compliance risk, and raise the cost of bringing products to market. The clearest “killer” use case is pharmacovigilance—capturing adverse events, processing safety cases, producing reports, and identifying signals quickly enough to protect patients and maintain a drug’s benefit-risk profile.
Product / Service
ArisGlobal sells LifeSphere, a cloud-native, integrated life-sciences software suite. Its Safety products provide a unified SaaS environment for pharmacovigilance operations, while the broader platform supports regulatory submissions, clinical data, quality, and related workflows. Automation spans intake, case management, literature assessment, reporting, analytics, and signal management; AI capabilities, including the NavaX cognitive-computing and generative-AI technology, are designed to reduce manual processing and enable more touchless safety operations. The delivery model is enterprise cloud software, with centralized updates intended to support global standardization, scalability, and ongoing regulatory compliance.
Market
ArisGlobal competes in life-sciences R&D and regulatory technology, particularly pharmacovigilance, drug-safety, regulatory-affairs, quality, and clinical-research software. Its competitive set includes Oracle Argus Safety, Veeva Vault Safety, Ennov PV Works, IQVIA, MasterControl, and other specialized regulatory and safety platforms. The company is a scaled commercial vendor rather than a pre-revenue startup: a July 2026 transaction announcement said it served more than 200 enterprise customers, including half of the world’s top 50 biopharma companies, processed more than 12 million safety cases annually, and was expected to generate approximately $175 million of 2026 revenue. The same announcement said Nordic Capital had agreed to sell the company to Dassault Systèmes, subject to the transaction’s completion.
Founders & Leadership
Funding History
Athyrium Capital Management, Abbhi Capital
Nordic Capital
Nordic Capital
Recent News
Dassault Systèmes announced an agreement to acquire ArisGlobal and combine its capabilities into a unified AI intelligence platform for life sciences. The transaction was expected to close in the second half of 2026.
ArisGlobal introduced AI-enabled Medical Information capabilities, including conversational AI for specialist guidance and self-service responses. The company said the capabilities can reduce manual data entry by up to 80%.
Two leading global pharmaceutical organizations selected ArisGlobal’s AI-enabled LifeSphere Regulatory platform to modernize regulatory information management and accelerate product development. Embedded NavaX capabilities automate routine work and surface actionable insights while supporting compliance.
Two additional global pharmaceutical organizations selected NavaX AI to streamline global pharmacovigilance operations. ArisGlobal said customers were adopting NavaX as a scalable AI foundation across pharmacovigilance, regulatory, quality, and medical affairs.
ArisGlobal announced a NavaX-powered LifeSphere Quality suite designed to connect Quality, Regulatory, Safety, and Medical Affairs in one ecosystem. The offering is intended to improve compliance, decision-making, execution, and continuous improvement.
ArisGlobal expanded its NavaX Agents suite with three AI agents designed to streamline regulatory and safety processes. The new agents were scheduled to become available in the fourth quarter of 2026.
ReporterX combines NavaX-powered dynamic data extraction, translation, conversational AI, and intelligent follow-up management for adverse-event, medical-information, and product-quality reporting. The system identifies missing information and helps collect more complete data at initial contact.
ArisGlobal reported strong 2025 performance and entered 2026 focused on scaling enterprise AI and expanding its role as a data-intelligence and technology partner for life sciences organizations. The update highlighted continued demand for AI-enabled modernization and advances to the LifeSphere platform.
ArisGlobal launched the NavaX Agents suite, with planned agents covering areas such as assessment, distribution, and regulatory intelligence. The announcement described upcoming releases spanning 2025 and 2026.
ArisGlobal announced a strategic partnership with Cognizance Technologies to help public- and private-sector clients accelerate transformation and optimize processes. The partnership targets digital transformation in life sciences and government.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
ArisGlobal monetizes LifeSphere and related products as enterprise SaaS solutions sold to life-sciences organizations, generating software revenue through its cloud platform. The available evidence does not disclose detailed per-seat, usage-based, or implementation pricing.
Products
Customers
Tech Stack
Similar Companies
Competitors
Key Investors
Nordic Capital, Athyrium Capital Management